Method for preparing pyrrolidone
US-2024132925-A1 · Apr 25, 2024 · US
Modified lipopolysaccharide glycoform and method of use
US9677052B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9677052-B2 |
| Application number | US-201514707718-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 8, 2015 |
| Priority date | May 9, 2014 |
| Publication date | Jun 13, 2017 |
| Grant date | Jun 13, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure describes genetic engineering of E. coli to create mutant O-antigen ligase, as well as novel lipopolysaccharide molecules resulting from that genetic engineering. Methods for using those novel molecules are also described.
First claim
Opening claim text (preview).
What is claimed is: 1. A mutant O-antigen ligase comprising an isolated protein that has the amino acid sequence SEQ ID NO: 1. 2. A mutant O-antigen ligase comprising an isolated protein having at least 90% sequence identity to SEQ ID NO: 2 and having an amino acid substitution of phenylalanine to serine at the phenylalanine homologous to position 332 of SEQ ID NO: 2, wherein the protein has at least one of O-antigen ligase activity or the activity to ligate lipid A to disaccharide pentapeptide (DPP). 3. A polynucleotide comprising a polynucleotide sequence encoding the mutant O-antigen ligase of claim 1 or 2 . 4. A method for generating an LPS molecule comprising the steps of: providing an E. coli strain adapted to express the mutant O-antigen ligase of claim 1 or 2 ; growing the E. coli strain; and isolating the LPS molecule. 5. The method of claim 4 , wherein isolating the LPS molecule comprises separating the LPS molecules based on at least one of the group consisting of size, chemical composition, and affinity for a particular binding agent.
Assignees
Inventors
Classifications
Lipopolysaccharides; Lipid A; Monophosphoryl lipid A · CPC title
attached to an oxygen atom of the saccharide radical · CPC title
Fatty acids · CPC title
Proteins; Peptides · CPC title
from bacteria · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9677052B2 cover?
- The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure describes genetic engineering of E. coli to create mutant O-antigen ligase, as well as novel lipopolysaccharide molecules resulting from that genetic engineering. Methods for using those novel molecules are also described.
- Who is the assignee on this patent?
- Silhavy Thomas J, Grabowicz Marcin, Kahne Daniel, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification C12N9/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).